Drug target for idiopathic pulmonary fibrosis
By identifying AREG signaling in AT2 cells as a drug target for idiopathic pulmonary fibrosis, regulating the expression of AREG and EGFR, the problem of poor treatment of IPF in the prior art is solved, and effective pulmonary fibrosis is achieved Regulation and diagnosis.
Patent Information
- Application Number
- CN202411075070.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2019-05-30
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art cannot effectively treat idiopathic pulmonary fibrosis (IPF), and lacks ideal drug targets for pulmonary fibrosis, resulting in limited therapeutic effects.
Identify and utilize AREG signaling in AT2 cells in the lung as a drug target, and regulate the development of pulmonary fibrosis by overexpressing or inhibiting AREG and its receptor EGFR.
It significantly weakens the development of pulmonary fibrosis, provides potential targets and diagnostic tools for the treatment of IPF, and improves the understanding and therapeutic effect of pulmonary fibrosis.
Smart Images

Figure SMS_2 
Figure SMS_3 
Figure SMS_4
Abstract
Description
Background Art
[0001] Fibrosis is the thickening and scarring of connective tissue caused by injury and is characterized by excessive proliferation of fibroblasts and accumulation of extracellular matrix (ECM) components. The disease is commonly observed in organs including the lungs, liver, and kidneys, leading to the destruction of tissue architecture and severe impairment of organ function. 1,2 In fact, fibrosis can occur in almost every organ and is the leading cause of end-stage organ failure and death in many chronic diseases. 3 A common feature of pulmonary fibrosis is the excessive proliferation of fibroblasts around the air sacs (alveoli) of the lungs. 4 Extensive biomedical research has established that an increase in the number of fibroblasts coupled with their excessive ECM deposition in the lungs ultimately leads to the destruction of alveolar architecture, decreased lung compliance, and disruption of gas exchange function. 5-7 .
[0002] The most common type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). This disorder eventually affects an entire lobe of the lung, but it begins with microfibrotic lesions in the peripheral areas and slowly progresses inwards. This fibrosis can eventually lead to respiratory failure. 8,9 IPF is a fatal disease with a median survival of only 2 to 4 years from the time of diagnosis. 10 Scientifically, the mechanism and nature of the pathological progression of IPF are not yet fully understood, but several studies have shown that a specific subpopulation of alveolar epithelial cells, alveolar type II (AT2) cells, play a role in the pathogenesis of IPF. 4,11 .
[0003] In patients with pulmonary fibrosis, lung compliance is reduced, gas exchange is disrupted, and respiratory failure and death eventually occur. It is estimated that in the United States, 1 in 200 adults over the age of 65 suffer from IPF, with a median survival of 2 to 4 years. Patients usually survive only 2 to 5 years.
[0004] Currently, IPF has no cure. Two known drugs, nintedanib and pirfenidone, have similar effects on the rate of decline in forced vital capacity over one year. Although both drugs showed a trend to reduce mortality, they did not show a significant increase in survival time. One of the main reasons is that there is currently no ideal drug target for pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), in order to screen candidate drugs for the treatment of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). Summary of the invention
[0005] The present invention relates to a drug target for idiopathic pulmonary fibrosis and its use. The drug target is AREG signaling in AT2 cells of the lung. The drug target can be used to screen drugs for treating and / or preventing pulmonary fibrosis in animals and humans, especially idiopathic pulmonary fibrosis (IPF). The present invention also provides a method for screening candidate drugs for treating pulmonary fibrosis in animals and humans, especially idiopathic pulmonary fibrosis (IPF) using the drug target.
[0006] First, the present invention provides a drug target for idiopathic pulmonary fibrosis. The drug target is AREG signal transduction in AT2 cells of the lung, which is hereinafter referred to as AREG target.
[0007] In the present invention, it was found that AREG was detected in AT2 cells of all IPF samples, but not in AT2 cells of control lungs.
[0008] In the present invention, it was found that AREG signal could not be detected in control lungs of subjects who had or had not undergone PNX.AREG signal could not be detected in AT2 cells of control lungs of subjects who had or had not undergone PNX.
[0009] The present invention further found that AREG can be detected in AT2 cells of Cdc42 AT2 gene null lungs. After PNX, the expression level of AREG in Cdc42 AT2 gene null lungs gradually increased.
[0010] Therefore, the expression level of AREG was significantly upregulated in both the progressive fibrosis mouse model and AT2 cells from patients with pulmonary fibrosis.
[0011] It was also found in the present invention that overexpression of AREG in AT2 cells is sufficient to induce lung fibrosis.
[0012] Preferably, ectopic expression of AREG in AT2 cells is sufficient to induce lung fibrosis.
[0013] Preferably, the AREG target is AREG in AT2 cells from the lung of a subject.
[0014] Preferably, the AREG target is a receptor for AREG in AT2 cells from the lung of a subject.
[0015] Preferably, the AREG target is EGFR in fibroblasts from the lung of a subject.
[0016] The present invention demonstrates that the intensity of EGFR signaling in α-SMA-positive fibroblasts depends on the expression of AREG in AT2 cells.
[0017] The present invention demonstrates that reducing the AREG expression level in AT2 cells of the lung of a subject significantly attenuates the development of pulmonary fibrosis in Cdc42 AT2 gene null mice.
[0018] Therefore, the present invention demonstrates that AREG and its receptor EGFR are therapeutic targets for treating fibrosis.
[0019] Secondly, the present invention provides a method for producing Areg AT2 overexpressing transgenic mice, wherein AREG is specifically overexpressed in lung AT2 cells.
[0020] Preferably, the method comprises the step of specifically inducing Areg expression in AT2 cells after doxycycline treatment. Preferably, the transgenic mouse produced is a Spc-rtTA;teto-Areg mouse. Preferably, the Spc-rtTA;teto-Areg mouse has a characteristic sequence shown by SEQ ID NO: 18.
[0021] Preferably, the following primer sequences can be used to identify the Spc-rtTA;teto-Areg mice:
[0022] Forward: GTACCCGGGATGAGAACTCCG (SEQ ID NO: 19);
[0023] Reverse: GCCGGATATTTGTGGTTCATT (SEQ ID NO: 20).
[0024] Thirdly, the present invention provides a transgenic mouse, wherein AREG is specifically overexpressed in AT2 cells of the lung. The mouse is a transgenic mouse in which AREG is overexpressed.
[0025] Preferably, in the transgenic mouse, the expression of Areg is specifically induced in AT2 cells after treatment with doxycycline. Preferably, the transgenic mouse is a Spc-rtTA;teto-Areg mouse. Preferably, the Spc-rtTA;teto-Areg mouse has a characteristic sequence shown by SEQ ID NO: 18.
[0026] Preferably, the Spc-rtTA;teto-Areg mice can be identified using the following primer sequences:
[0027] Forward: GTACCCGGGATGAGAACTCCG (SEQ ID NO: 19);
[0028] Reverse: GCCGGATATTTGTGGTTCATT (SEQ ID NO: 20).
[0029] Fourthly, the present invention provides the use of AREG in AT2 cells of the lung and / or its receptor EGFR in fibroblasts as drug targets for treating pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), in animals and humans.
[0030] Fifth, the present invention provides the use of AREG target or the above transgenic mouse for screening drugs for treating pulmonary fibrosis in animals and humans, especially idiopathic pulmonary fibrosis (IPF).
[0031] Sixth, the present invention provides the use of a detection agent for AREG and / or a detection agent for its receptor EGFR in the manufacture of a diagnostic kit for diagnosing pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), in animals and humans.
[0032] Preferably, the kit can be used for samples from subjects suspected of suffering from pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The sample can be a biopsy. For example, the biopsy can be lung tissue of the subject. Preferably, the biopsy can be the lower, middle or upper part of the subject's lung lobe. If AREG can be detected in the upper part of the subject's lung lobe, the subject can be diagnosed as suffering from severe pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The most common type of pulmonary fibrosis is considered to be idiopathic pulmonary fibrosis, in which fibrotic lesions begin at the periphery of the lung lobe and develop toward the center of the lung lobe, then the upper part of the lung lobe, and eventually lead to respiratory failure.
[0033] Seventh, the present invention provides a substance targeting AREG and / or its receptor (such as EGFR in fibroblasts) in pulmonary AT2 cells, and its use in the manufacture of a drug for treating pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), in animals and humans.
[0034] Preferably, the substance is an inhibitor of AREG in lung AT2 cells, or an inhibitor of EGFR in lung fibroblasts.
[0035] The animal can be a mouse, rabbit, rat, dog, pig, horse, cow, sheep, monkey or chimpanzee.
[0036] The present invention covers all combinations of the specific embodiments described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 The construction of a mouse strain in which the Cdc42 gene is specifically deleted in AT2 cells is shown.
[0038] Figure 2Fragments of the Cdc42 DNA sequence before and after deletion of exon 2 of the Cdc42 gene in AT2 cells are shown.
[0039] Figure 3 We show that deletion of the Cdc42 gene in AT2 cells impairs AT2 cell differentiation during alveolar regeneration or alveolar homeostasis after PNX.
[0040] Figure 4 We show that loss of Cdc42 in AT2 cells leads to progressive pulmonary fibrosis in PNX-treated mice.
[0041] Figure 5 showed that loss of Cdc42 in AT2 cells resulted in progressive pulmonary fibrosis in aged mice without PNX treatment.
[0042] Figure 6 In the lungs of Cdc42 AT2 null mice, α-SMA + Development of fibroblastic foci.
[0043] Figure 7 AREG was strongly and specifically expressed in AT2 cells of the lungs null for Cdc42 AT2.
[0044] Figure 8 It was shown that AREG was strongly and specifically expressed in AT2 cells from human pulmonary fibrosis patients.
[0045] Fig. 9 The sequence of teto-Areg is shown.
[0046] Fig.10 We showed that Areg expression was specifically induced in AT2 cells of Spc-rtTA;teto-Areg mice after doxycycline treatment. Overexpression of AREG in AT2 cells was sufficient to induce pulmonary fibrosis.
[0047] Fig.11 Shown are fragments of the Areg DNA sequence before and after exon 3 of the Areg gene in AT2 cells that are deleted.
[0048] Fig.12 It was shown that the loss of Areg gene significantly attenuated the development of pulmonary fibrosis in AT2 cells of the lungs in which the Cdc42 AT2 gene was null.
[0049] Fig.13 Targeting AREG and its receptor EGFR is indicated for the treatment of IPF and other fibrotic diseases. DETAILED DESCRIPTION
[0050] The descriptions of specific embodiments and examples are provided by way of illustration rather than limitation. Those skilled in the art will readily recognize that a variety of noncritical parameters may be changed or modified to produce substantially similar results.
[0051] Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive and irreversible decline in lung function. Symptoms typically include gradual onset of shortness of breath and a dry cough. Other changes may include feeling tired and clubbing of the fingers. Complications may include pulmonary hypertension, heart failure, pneumonia, or pulmonary embolism.
[0052] The alveolar epithelium of the lung is composed of a combination of type I (AT1) and type II (AT2) alveolar cells. AT2 cells are alveolar stem cells and can differentiate into AT1 cells during alveolar homeostasis and post-injury repair. 12,13 AT1 cells, which ultimately make up almost 95% of the alveolar surface in the adult lung, are large squamous cells that function as the epithelial portion of the thin air-blood barrier. 14 In IPF tissue, abnormally proliferating AT2 cells are often located near fibroblast foci. 15 In clinical practice, gene mutations that affect AT2 cell function are often found in IPF tissues. 16,17 In addition, recent advances have revealed that TGFβ signaling, a common fibrotic signaling pathway in many fibrotic diseases, is activated in AT2 cells of IPF lungs by identifying molecular expression profiles of IPF lungs. 18 These multiple lines of evidence together demonstrate that AT2 cells have a significant pathological impact in pulmonary fibrosis, but the exact pathological mechanism of AT2 physiological abnormalities and progressive pulmonary fibrosis remains to be elucidated.
[0053] After the animals were given tamoxifen, the Sftpc gene promoter-driven recombinase (Spc-CreER) specifically deleted the gene in AT2 cells. The CreER mouse system is often used for inducible gene knockout studies.
[0054] Amphiregulin (AREG) is a member of the epidermal growth factor family. AREG is synthesized as a membrane-anchored precursor protein that can act directly on neighboring cells as a juxtacrine factor. After proteolytic processing by cellular membrane proteases (TACE / ADAM17), AREG is secreted and functions as an autocrine or paracrine factor. AREG is a ligand for the epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase. By binding to EGFR, AREG can activate important intracellular signaling cascades that control cell survival, proliferation, and differentiation. 19-21 .
[0055] Physiologically, AREG plays an important role in the development and maturation of mammary glands, bone tissues and oocytes. 20,22 Under normal conditions, AREG is expressed at low levels in adult tissues other than the placenta. However, chronic elevation of AREG expression has been shown to be associated with certain pathological conditions. Elevated expression of AREG is associated with a psoriasis-like skin phenotype and certain inflammatory conditions. 23 Multiple studies have described the oncogenic activity of AREG in lung, breast, colorectal, ovarian, and prostate cancers, as well as in some hematologic and mesenchymal cancers. 24,25 In addition, AREG may be involved in resistance to several cancer therapies. 26,27 .
[0056] Studies have shown that TGFβ can activate the expression of AREG in a mouse model of bleomycin-induced pulmonary fibrosis 28 AREG expression levels have been shown to be elevated in liver fibrosis, cystic fibrosis, and polycystic kidney disease 23 Therefore, it can be hypothesized that AREG may promote the growth and survival of fibrogenic cells during these fibrotic diseases, especially idiopathic pulmonary fibrosis (IPF). However, scientifically speaking, the mechanism and nature of the pathological progression of IPF are not yet fully understood. 29 Although AREG has been speculated to play a role in IPF development, the cells expressing AREG during progressive pulmonary fibrosis remain unknown. Furthermore, due to the lack of a mouse model of progressive pulmonary fibrosis, the role of targeting AREG in progressive pulmonary fibrosis is also unknown.
[0057] In one embodiment of the present invention, it is shown that AREG signal is not detectable in control lungs of subjects with or without PNX, and further, AREG signal is not detectable in AT2 cells of control lungs of subjects with or without PNX.
[0058] In one embodiment of the present invention, AREG was detected in AT2 cells of Cdc42 AT2 null lungs or aged Cdc42 AT2 null mice treated with PNX. After PNX, AREG expression levels gradually increased in the lungs of Cdc42 AT2 null lungs, and it is noteworthy that AREG was detected in AT2 cells of all IPF samples. Therefore, the present invention shows for the first time that AREG expression levels are significantly upregulated in AT2 cells of progressive fibrosis mouse models and patients with pulmonary fibrosis.
[0059] In one embodiment of the present invention, transgenic mice were generated in which AREG was specifically overexpressed in AT2 cells of the lung. The transgenic mice had obvious fibrotic changes in the lung.
[0060] In one embodiment of the present invention, transgenic mice are produced, in which the Areg gene and the Cdc42 gene are both null. This transgenic mouse is an Areg & Cdc42 AT2 double gene null mouse. Compared with the significant pulmonary fibrosis that occurs in the lungs in which the Cdc42 AT2 gene is null, the lungs of the Areg & Cdc42 AT2 double gene null mouse show very little fibrosis on the 21st day after PNX. Therefore, reducing the expression level of AREG significantly weakens the development of pulmonary fibrosis in the Cdc42 AT2 gene null mouse. Therefore, the present invention proposes that AREG and its receptor EGFR are therapeutic targets for treating fibrosis. AREG refers to AREG in the AT2 cells of the lung, and EGFR refers to EGFR on the fibroblasts of the lung.
[0061] In one embodiment of the present invention, it was shown that blocking AREG and its receptor EGFR could be a therapeutic approach for treating IPF and other fibrotic diseases.
[0062] Example
[0063] method
[0064] Mice and survival curve recording
[0065] Rosa26-CAG-mTmG (Rosa26-mTmG) and Cdc42 have been described previously. flox / flox Mouse 30 All experiments were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institute of Biological Sciences. To monitor the survival of mice, control and Cdc42 AT2 null mice were weighed weekly after PNX treatment. Mice were sacrificed once they reached the pre-determined endpoint criteria. We defined the endpoints according to the pre-determined criteria 31,32 .
[0066] Construction of Spc-CreER;rtTA (Spc-CreER) knock-in mice. CreERT2, p2a and rtTA elements were enzymatically ligated and inserted into the endogenous Sftpc gene of mice. The insertion site was the stop codon of the endogenous Sftpc gene, and then a new stop codon was created at the 3' end of rtTA. Using CRISPR / Cas9 technology, the CreERT2-p2a-rtTA fragment was inserted into the genome.
[0067] Building Areg flox / flox Mouse
[0068] Building Areg following previous work flox / flox Mouse 33In brief, Areg exon 3 was anchored by loxp. loxp1 (GACACGGATCCATAACTTCGTATAATG TATGCTATACGAAGTTATCGAGTC (SEQ ID NO: 3)) was inserted into position 3704 of Areg DNA, and loxp2 (CCGCGGATAACTTCGTATAATGTATGCTATACGAAGTTATACTAGTCCAACG (SEQ ID NO: 4)) was inserted into position 4208 of Areg DNA. After tamoxifen-induced Cre-loxP recombination, exon 3 of the Areg gene was deleted, thereby blocking the function of AREG.
[0069] Construction of teto-Areg mice
[0070] Inserting a tetracycline response element before Areg driven by the CMV promoter can induce the expression of Areg when mice are treated with doxycycline (Dox). The sequence of the tetracycline response element is shown below: 5'TCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGA3' (SEQ ID NO: 5).
[0071] A minimal CMV promoter was inserted before the Areg cDNA to overexpress Areg. The sequence of the CMV promoter is shown below:
[0072] 5'GGTAGGCGTGTACGGTGGGAGGCCTATATAAGCAGAGCT3' (SEQ ID NO: 6).
[0073] The sequence of Areg cDNA is shown below:
[0074] 5’ATGAGAACTCCGCTGCTACCGCTGGCGCGCTCAGTGCTGTTGCTGCTGGTCTTAGG CTCAGGCCATTATGCAGCTGCTTTGGAGCTCAATGACCCCAGCTCAGGGAAAGGCGAATCGCTTTCTGGGGACCACAGTGCCGGTGGACTTGAGCTTTCTGTGGGAAGAGAGGTTTCCACCATAAGCGAAATGCCTTCTGGCAGTGAACTCTCCACAGGGGACTACGACTACTCAGAGGAGTATGATAATGAACCACAAATATCCGGCTATATTATAGATGATTCAGTCAGAGTTGAACAGGTGATTAAGCCCAAGAAAAACAAGACAGAAGGAGAAAAGTCTACAGAAAAACCCAAAAGGAAGAAAAAGGGAGGCAAAAATGGAAAAGGCAGAAGGAATAAGAAGAAAAAGAATCCATGCACTGCCAAGTTTCAGAACTTTTGCATTCATGGCGAATGCAGATACATCGAGAACCTGGAGGTGGTGACATGCAATTGTCATCAAGATTACTTTGGTGAACGGTGTGGAGAAAAATCCATGAAGACTCACAGCGAGGATGACAAGGACCTATCCAAGATTGCAGTAGTAGCTGTCACTATCTTTGTCTCTGCCATCATCCTCGCAGCTATTGGCATCGGCATCGTTATCACAGTGCACCTTTGGAAACGATACTTCAGGGAATATGAAGGAGAAACAGAAGAAAGAAGGAGGCTTCGACAAGAAAACGGGACTGTGCATGCCATTGCCTAG3’(SEQ ID NO:7).
[0075] The tetracycline response element, CMV promoter, and Areg cDNA were ligated enzymatically and inserted into the mouse genome. The sequence of teto-Areg is shown below:
[0076]
[0077] In Spc-rtTA;teto-Areg mice, Areg expression was specifically induced in AT2 cells after doxycycline treatment.
[0078] Primer sequences used for sequencing teto-Areg sequences:
[0079] Forward: GTACCCGGGATGAGAACTCCG (SEQ ID NO: 19);
[0080] Reverse: GCCGGATATTTGTGGTTCATT (SEQ ID NO: 20).
[0081] Pneumonectomy (PNX)
[0082] 8-week-old male mice were injected with tamoxifen (dose: 75 mg / kg) every other day for a total of 4 injections. On the 14th day after the last dose of tamoxifen, the mice were anesthetized and connected to a ventilator (Kent Scientific, Topo). The chest wall was cut open at the fourth intercostal space and the left lung lobe was removed.
[0083] Lung function tests
[0084] Using the invasive lung function test system (DSI Pulmonary function parameters were measured using the PFT controller. Mice were first anesthetized and then an endotracheal tube was inserted into their trachea. Arterial compliance results were obtained from resistance and compliance tests. Forced vital capacity results were obtained from pressure volume tests.
[0085] Hematoxylin and eosin (H&E) staining and immunostaining
[0086] Lungs were filled with 4% paraformaldehyde (PFA) and fixed continuously in 4% PFA for 24 hours at 4° C. Lungs were then cryoprotected in 30% sucrose and embedded in OCT (Tissue Tek).
[0087] H&E staining experiments followed standard H&E protocols. Briefly, slides were washed with water to remove OCT. Nuclei were stained with hematoxylin (Abcam, ab150678) for 2 minutes, and cytoplasm was stained with eosin (Sigma, HT110280) for 3 minutes. After dehydration and clarification steps, sections were sealed with neutral resin.
[0088] Immunofluorescence staining experiments followed previously described protocols. 34Briefly, after removing OCT, lung sections were blocked with 3% BSA / 0.1% TritonX-100 / PBS for 1 hour, and then sections were incubated with primary antibodies overnight at 4°C. After the slides were washed three times with 0.1% TritonX-100 / PBS, the slides were incubated with secondary antibodies at room temperature for 2 hours.
[0089] The primary antibodies used in this article are listed below:
[0090]
[0091] The secondary antibodies used in this article are listed below:
[0092]
[0093]
[0094] For p-SMAD2 staining experiments, 1× phosphatase inhibitor (Bimake, B15002) was added to 4% PFA during tissue fixation. pSMAD2 staining was performed using tyramide signal amplification.
[0095] Human lung tissues were fixed with 4% PFA for 24 h at 4°C, cryoprotected in 30% sucrose and embedded in OCT. All experiments were performed with the approval of the Institutional Review Boards of both the Beijing Institute of Life Sciences and the Beijing China-Japan Friendship Hospital.
[0096] Statistical analysis. All data are presented as mean ± sem (as shown in the legend). The data presented in the figure are collected from multiple independent experiments performed on different days using different mice. Unless otherwise stated, most of the data presented in the figure are based on at least three independent experiments. The statistical significance of the inference of the differences between samples was evaluated using a two-tailed unpaired Student's t-test.
[0097] Isolation of mouse AT2 cells
[0098] After 4 doses of tamoxifen, lungs of Spc-CreER, Rosa26-mTmG mice were isolated as described previously. 23 Briefly, anesthetized mice were perfused with neutral protease (Worthington-Biochem, LS02111) and DNase I (Roche, 10104159001). AT2 cells were directly sorted based on GFP fluorescence using single cell selection mode in BD FACS Aria II and III instruments.
[0099] Quantitative RT-PCR (qPCR)
[0100] Total RNA was isolated from whole lung or primary AT2 cells using the Zymo Research RNA Miniprep Kit (R2050). Reverse transcription was performed using the Two-Step cDNA Synthesis Kit (Takara, Cat. No. 6210A / B) following the manufacturer's recommendations. qPCR was performed using the CFX96 Touch TM Real-time PCR detection system was used. The target gene mRNA level was normalized with the Gapdh mRNA level. The primers used for qPCR are listed below.
[0101] Primers used for qPCR are listed below.
[0102]
[0103] AREG ELISA
[0104] Using mouse AREG immunoassay kit (R&D Systems, DY989), the AREG concentration of whole lung lysate is detected. Specifically, the whole lung lobe is ground in liquid nitrogen, and then lysed using cell lysis buffer. Then the lung lysate is added to the hole of the microplate used. After the reaction, the absorbance at 450nm is measured. Using human areg immunoassay kit (abnova, B0RB01090J00018), the AREG concentration of human lung tissue lysate is detected. In simple terms, human lung tissue is ground in liquid nitrogen, and then lysed using cell lysis buffer. Then the lung lysate is added to the hole of the microplate used. After the reaction, the absorbance at 450nm is measured. All experiments were carried out with the approval of the Institutional Review Board of both Beijing Institute of Life Sciences and Beijing Sino-Japanese Friendship Hospital.
[0105] Primer sequences used to sequence Cdc42 DNA sequence fragments before and after the deletion of exon 2 of Cdc42:
[0106] Forward: CTGCCAACCATGACAACCTAA (SEQ ID NO: 1);
[0107] Reverse: AGACAAAACAACAAGGTCCAG (SEQ ID NO: 2).
[0108] Primer sequences used to sequence the Areg DNA sequence fragments before and after the deletion of exon 3 of Areg:
[0109] Forward: AAACAAAACAAGCTGAAATGTGG (SEQ ID NO: 14);
[0110] Reverse: AAGGCCTTTAAGAACAAGTTGT (SEQ ID NO: 15).
[0111] Example 1. Construction and characterization of Cdc42 AT2 gene null mice
[0112] In order to construct an animal model of progressive pulmonary fibrosis, Cdc42 AT2 gene-null mice were generated by specifically knocking out the Cdc42 gene in alveolar type II cells (AT2).
[0113] To specifically delete the Cdc42 gene in AT2 cells, mice carrying the Spc-CreER allele were transfected with Cdc42 flanked by loxp sites (floxed) (Cdc42 flox / flox ) mouse hybrid( Figure 1 A). In Cdc42 flox / flox In mice, exon 2 of the Cdc42 gene (which contains the translation start exon of the Cdc42 gene) is flanked by two loxP sites. flox / flox In mice, exon 2 of the Cdc42 gene was specifically deleted in AT2 cells by Cre / loxp-mediated recombination after tamoxifen treatment ( Figure 1 B) Spc-CreER; Cdc42 flox / flox The mice were named Cdc42 AT2 gene null mice.
[0114] Figure 2 Shown in FIG. 1 are fragments of the Cdc42 DNA sequence before and after deletion of exon 2 of the Cdc42 gene.
[0115] We performed PNX in control and Cdc42 AT2 null mice and analyzed alveolar regeneration and AT2 cell differentiation at day 21 after PNX ( Figure 3 A). Figure 3 As shown in A, 200 μm lung sections from control and Cdc42 AT2 null mice were immunostained with antibodies against GFP, Pdpn, and Prospc. On day 21 after PNX, many newly differentiated AT1 cells and newly formed alveoli were observed in control lungs without implantation ( Figure 3 B). However, in Cdc42 AT2 gene null lungs, few AT2 cells differentiated into AT1 cells and no new alveoli were formed at day 21 after PNX ( Figure 3 B). It was observed that alveoli in the peripheral regions of Cdc42 AT2 gene-null lungs were severely overstretched ( Figure 3 B).
[0116] Under normal homeostatic conditions, AT2 cells slowly self-renew and differentiate into AT1 cells to establish new alveoli. To examine whether Cdc42 is required for AT2 cell differentiation during homeostasis, we deleted the Cdc42 gene in AT2 cells at 2 months of age and analyzed the fate of AT2 cells until 12 months of age. Lungs of control and non-PNX-treated Cdc42 null mice were collected at 12 months of age. Figure 3 C). The image shows a 200 μm Z-projection of a lung section at maximum intensity stained with antibodies against GFP, Pdpn and Prospc. In the lungs of 12 month old control mice, we observed the formation of many new alveoli ( Figure 3 D). However, in the lungs of 12-month-old Cdc42-null mice (not subjected to PNX), we observed enlarged alveoli and the absence of any new AT1 cell formation ( Figure 3 D).
[0117] After PNX, Cdc42 AT2 null and control mice were observed for a longer period of time ( Figure 4 A). Surprisingly, at day 21 after PNX, some Cdc42 AT2 null mice showed significant weight loss and increased respiratory rate. In fact, at day 60 after PNX, almost 50% of the PNX-treated Cdc42 AT2 null mice reached the predetermined health status criteria for endpoint euthanasia ( Figure 4 B), and by day 180 after PNX, approximately 80% of PNX-treated Cdc42AT2 null mice reached their endpoint ( Figure 4 B).
[0118] H&E staining of control and Cdc42 AT2 null mice after PNX revealed severe fibrosis in the lungs of Cdc42 AT2 null mice at their endpoint ( Figure 4 D and Figure 4 To determine the time point when Cdc42AT2 null mice begin to develop pulmonary fibrosis after PNX, the lungs of Cdc42AT2 null mice were analyzed using H&E staining at various time points after PNX ( Figure 4 D) Before day 21 after PNX, some Cdc42 AT2 null lungs showed signs of tissue thickening in the subpleural region ( Figure 4 D) By the end point, dense fibrosis had progressed to the center of most Cdc42 AT2 null lungs ( Figure 5D) The situation we observed in post-PNX and aged Cdc42-null mice resembles the characteristic progression of IPF, where fibrotic lesions first occur at the periphery of the lung and then progress inward toward the center of the lobes.
[0119] In addition to the strong immunofluorescence signal of type I collagen detected in these dense fibrotic areas of the lungs of Cdc42 AT2 null mice ( Figure 4 In addition, we observed that the proportion of areas expressing type I collagen in each lung lobe increased gradually after PNX in Cdc42 AT2 null mice ( Figure 4 F). Our qPCR analysis also showed that the mRNA expression level of type I collagen gradually increased from day 21 after PNX ( Figure 4 G). Furthermore, a progressive decrease in lung compliance was observed in PNX-treated Cdc42 AT2 null mice starting from day 21 after PNX compared with their PNX-treated control mice ( Figure 4 H), an interesting finding considering that a decrease in lung compliance is known to often occur when the lung becomes fibrotic.
[0120] Because impaired AT2 differentiation and alveolar enlargement were found in 12-month-old Cdc42 AT2 null mice ( Figure 3 D), lungs of non-PNX-treated control and Cdc42 AT2 null mice were analyzed from 10 to 24 months of age ( Figure 5 A). Fibrotic changes were never observed in the lungs of control mice even when they reached 24 months of age ( Figure 5 B). We did not observe significant fibrotic changes in Cdc42 AT2 null mice until they reached 10 months of age ( Figure 5 C). It was also observed that fibrosis had already begun to develop significantly in the subpleural region of the Cdc42 AT2 gene-null lungs before 12 months and progressed toward the center of the lungs after 12 months ( Figure 5 C).
[0121] Fibroblastic foci are considered to be relevant morphological markers of progressive pulmonary fibrosis and are considered to be sites of initiation and / or persistence of the fibrotic response in progressive pulmonary fibrosis. 35 Fibroblast foci contain proliferating α-SMA + Fibroblasts. Lungs of Cdc42 AT2 null mice were stained with an antibody against α-SMA at day 21 after PNX ( Figure 6 A). Some α-SMA was observed in relatively normal alveolar areas of Cdc42 AT2 null lungs. +Fibroblasts began to gather near the AT2 cell cluster (area 1, Figure 6 A). The dense fibrotic areas of the lung are filled with α-SMA + Fibroblasts (region 2, Figure 6 A). In addition, by immunostaining with antibodies against both α-SMA and the proliferation marker Ki67, we showed that α-SMA was expressed at day 21 after PNX. + Cell proliferation was dramatically increased in the lungs of Cdc42 AT2 null mice. These results suggest that proliferative α-SMA + Fibroblasts promote the development of pulmonary fibrosis in Cdc42 AT2 null mice Figure 6 B).
[0122] In summary, loss of Cdc42 in AT2 cells led to progressive pulmonary fibrosis in PNX-treated mice. In addition, this progressive pulmonary fibrosis phenotype also occurred in Cdc42 AT2 gene null mice that were not treated with PNX, starting around 12 months of age. All these results confirmed that loss of Cdc42 in AT2 cells led to IPF-like progressive pulmonary fibrosis in mice, thus establishing an IPF-like progressive pulmonary fibrosis mouse model that can be used to study human IPF disease.
[0123] Example 2. Sequence Characterization of Cdc42 AT2 Gene Null Mice
[0124] Spc-CreER,Cdc42 flox / - Mouse genome was purified and PCR amplified. Cdc42 flox and gene null bands were then purified and sequenced using primers as described below:
[0125] CTGCCAACCATGACAACCTAA(SEQ ID NO: 1);
[0126] AGACAAAACAACAAGGTCCAG (SEQ ID NO: 2).
[0127] Figure 2 Fragments of the Cdc42 DNA sequence before or after the deletion of exon 2 of the Cdc42 gene are shown in FIG.
[0128] Example 3. Amphiregulin (AREG) is strongly expressed in AT2 cells of Cdc42 AT2 gene null lungs after PNX treatment
[0129] In the Cdc42 AT2 null fibrosis model, Cdc42 AT2 null lungs began to show fibrotic changes at day 21 after PNX ( Figure 4D). We have characterized control and Cdc42 null AT2 cells after PNX treatment ( Figure 7 A). By both RNA sequencing analysis and quantitative PCR (qPCR), Areg was observed to be one of the most upregulated genes in AT2 cells of Cdc42AT2 gene-null lungs at day 21 after PNX ( Figure 7 B). By immunostaining, AREG was detected in AT2 cells of Cdc42 AT2 gene null lungs on day 21 after PNX ( Figure 7 C). AREG signal was not detected in control lungs at day 21 after PNX ( Figure 7 C), which is consistent with the information from the human tissue atlas that AREG expression is below detectable levels in adult lung tissue. In addition, AREG signals were specifically detected in AT2 cells. The expression of AREG protein in Cdc42 AT2 gene null lungs was measured by AREG ELISA kit. It was observed that in the lungs of Cdc42 AT2 gene null mice, the expression level of AREG gradually increased from day 21 after PNX to day 60 after PNX ( Figure 7 D).
[0130] Example 4. AREG is strongly expressed in AT2 cells from patients with pulmonary fibrosis
[0131] As shown in Example 3, a positive correlation between the expression level of AREG and the progression of pulmonary fibrosis was observed in Cdc42 AT2 gene null mice. The expression level of AREG in 2 donors and 3 IPF lungs was analyzed. Strikingly, AREG was detected in AT2 cells (cells expressing HTII-280) of all IPF samples, but not in AT2 cells of donor lungs ( Figure 8 A). The expression of AREG in the lungs of IPF patients and patients with autoimmune-induced pulmonary fibrosis was measured using an AREG ELISA kit. It was found that the expression level of AREG was significantly increased in the lungs of IPF patients and patients with autoimmune-induced pulmonary fibrosis ( Figure 8 B).
[0132] Taken together, these results show that AREG expression levels are significantly upregulated in AT2 cells from both a progressive fibrosis mouse model and patients with pulmonary fibrosis.
[0133] Example 5. Overexpression of AREG in AT2 cells is sufficient to induce pulmonary fibrosis
[0134] Generation of teto-Areg mice
[0135] The tetracycline response element was inserted before the Areg driven by the CMV promoter so that the expression of Areg could be induced when mice were treated with doxycycline (Dox). The sequence of the tetracycline response element is as follows: 5'TCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGA3' (SEQ ID NO: 5).
[0136] The minimal CMV promoter was inserted in front of the Areg cDNA to overexpress Areg. The sequence of the CMV promoter is shown below:
[0137] 5'GGTAGGCGTGTACGGTGGGAGG CCTATATAAGCAGAGCT3' (SEQ ID NO: 6).
[0138] The sequence of Areg cDNA is shown below:
[0139] 5’ATGAGAACTCCGCTGCTACCGCTGGCGCGCTCAGTGCTGTTGCTGCTGGTCTTAGG CTCAGGCCATTATGCAGCTGCTTTGGAGCTCAATGACCCCAGCTCAGGGAAAGGCGAATCGCTTTCTGGGGACCACAGTGCCGGTGGACTTGAGCTTTCTGTGGGAAGAGAGGTTTCCACCATAAGCGAAATGCCTTCTGGCAGTGAACTCTCCACAGGGGACTACGACTACTCAGAGGAGTATGATAATGAACCACAAATATCCGGCTATATTATAGATGATTCAGTCAGAGTTGAACAGGTGATTAAGCCCAAGAAAAACAAGACAGAAGGAGAAAAGTCTACAGAAAAACCCAAAAGGAAGAAAAAGGGAGGCAAAAATGGAAAAGGCAGAAGGAATAAGAAGAAAAAGAATCCATGCACTGCCAAGTTTCAGAACTTTTGCATTCATGGCGAATGCAGATACATCGAGAACCTGGAGGTGGTGACATGCAATTGTCATCAAGATTACTTTGGTGAACGGTGTGGAGAAAAATCCATGAAGACTCACAGCGAGGATGACAAGGACCTATCCAAGATTGCAGTAGTAGCTGTCACTATCTTTGTCTCTGCCATCATCCTCGCAGCTATTGGCATCGGCATCGTTATCACAGTGCACCTTTGGAAACGATACTTCAGGGAATATGAAGGAGAAACAGAAGAAAGAAGGAGGCTTCGACAAGAAAACGGGACTGTGCATGCCATTGCCTAG3’(SEQ ID NO:7).
[0140] The tetracycline response element, CMV promoter and Areg cDNA were ligated by enzymatic method and inserted into the mouse genome. The sequence of teto-Areg is shown below:
[0141] Fig. 9 ).
[0142] In Spc-rtTA;teto-Areg mice, Areg expression was specifically induced in AT2 cells after doxycycline treatment.
[0143] The primer sequences used for sequencing the teto-Areg sequence are as follows:
[0144] Forward: GTACCCGGGATGAGAACTCCG (SEQ ID NO: 19);
[0145] Reverse: GCCGGATATTTGTGGTTCATT (SEQ ID NO: 20).
[0146] To evaluate the function of elevated AREG expression in AT2 cells, transgenic mice overexpressing Areg AT2 were generated, in which Areg can be specifically overexpressed in AT2 cells. First, transgenic mice expressing Areg under the control of a tetracycline-responsive promoter element (tetO) were generated. Mice carrying the Spc-rtTA allele were crossed with mice carrying the teto-Areg allele to obtain offspring mice carrying Spc-rtTA;teto-Areg. When Spc-rtTA;teto-Areg mice were exposed to the tetracycline analog doxycycline (Dox), the expression of Areg was specifically induced in AT2 cells. The Spc-rtTA;teto-Areg mice were named Areg AT2OE Mouse ( Fig.10 A).
[0147] Areg AT2OE Mice were treated with water containing Dox for 21 days ( Fig.10 B) Aregs were then collected with or without Dox treatment AT2OE Lungs of mice were used for analysis. qPCR analysis showed that after Dox treatment, Areg AT2OE The expression of Areg mRNA was significantly induced in mouse AT2 cells ( Fig.10 C) H&E staining shows that Aregs treated with Dox AT2OE The lungs of mice showed obvious fibrotic changes ( Fig.10 D). Many cells in fibrotic areas express high levels of α-SMA ( Fig.10 E).
[0148] These results demonstrate for the first time that ectopic expression of AREG in AT2 cells is sufficient to induce lung fibrosis.
[0149] Example 6. Construction of Areg AT2 gene null mice
[0150] Generate Areg flox / flox Mouse: Areg flox / flox Mice were generated according to previous work 33 Briefly, Areg exon 3 was anchored by loxp. loxp1 (GACACGGATCCA TAACTTCGTATAATGTATGCTATACGAAGTTATCGAGTC (SEQ ID NO: 3)) was inserted into position 3704 of Areg DNA, and loxp2 (CCGCGGA TAACTTCGTATAATGTATGCTATACGAAGTTATACTAGTCCAACG (SEQ ID NO: 4)) was inserted into position 4208 of Areg DNA. After tamoxifen-induced Cre-loxP recombination, Areg exon 3 was deleted, thereby blocking AREG function.
[0151] Fig.11 Fragments of the Areg DNA sequence before or after the deletion of exon 3 of the Areg gene are shown in FIG.
[0152] Example 7. Deletion of the Areg gene in Cdc42 AT2 gene null cells significantly slowed the development of pulmonary fibrosis
[0153] Given the profibrotic function of AREG in AT2 cells, we evaluated whether reducing AREG expression in Cdc42 AT2 null lungs would attenuate the development of fibrosis. Areg flox mice were generated, in which exon 3 of the Areg gene is flanked by two loxp sites. Mice in which the Areg gene was deleted throughout the body were analyzed. - / - The mice were viable and fertile, indicating that the Areg gene is not essential for the survival and development of the mice. After several generations of crossbreeding, we obtained Areg&Cdc42 AT2 double gene null mice, in which both the Areg and Cdc42 genes were deleted in AT2 cells.
[0154] Next, the effects of Areg deletion in Cdc42 AT2 null cells were investigated. Control, Cdc42 AT2 null, and Areg & Cdc42 AT2 double null mice were exposed to 4 doses of tamoxifen ( Fig.12A). The lungs of these mice were analyzed at multiple time points after PNX. On day 21 after PNX, qPCR analysis showed that Areg expression levels were not increased in Areg & Cdc42 double gene null AT2 cells on day 21 after PNX, confirming the absence of the Areg gene in these AT2 cells ( Fig.12 B).
[0155] AREG binds to EGFR, which can activate the phosphorylation of EGFR. α-SMA was examined by immunostaining experiments using antibodies against GFP (labeling AT2 cells), p-EGFR, and α-SMA. + p-EGFR expression in fibroblasts. In lungs null for Cdc42AT2, strong expression of p-EGFR in α-SMA-positive fibroblasts was observed. Fig.12 C). In the lungs of Areg & Cdc42 AT2 double gene null, not only were far fewer α-SMA-positive fibroblasts detected, but also a decreased expression level of p-EGFR was observed ( Fig.12 C). This confirms that the strength of EGFR signaling in α-SMA-positive fibroblasts depends on the expression of AREG in AT2 cells. In addition, at day 21 after PNX, lungs of Areg & Cdc42 AT2 double gene nulls showed minimal fibrosis, compared to significant lung fibrosis in lungs of Cdc42 AT2 gene nulls ( Fig.12 D). The survival curve also showed that the Areg & Cdc42 AT2 double gene null mice had a significantly longer lifespan than the Cdc42 AT2 gene null mice ( Fig.12 E).
[0156] Together, these results demonstrate that reducing AREG expression levels in AT2 cells significantly attenuates the development of lung fibrosis in Cdc42 AT2 null mice. These results also suggest that AREG and its receptor EGFR are therapeutic targets for the treatment of fibrosis.
[0157] Example 8. Sequence Characterization of Mice Null for the Areg AT2 Gene
[0158] Spc-CreER,Areg flox / - The mice were subjected to genome purification and PCR amplification. Then, the Areg flox and gene null bands were purified and sequenced using the following primers:
[0159] AAACAAAACAAGCTGAAATGTGG (SEQ ID NO: 14);
[0160] AAGGCCTTTAAGAACAAGTTGT (SEQ ID NO: 15).
[0161] Example 9. Targeting AREG and its receptor EGFR to treat IPF and other fibrotic diseases
[0162] Considering that EGFR can be activated by AREG in α-SMA-positive fibroblasts ( Fig.12 Based on this fact, we investigated the effect of inhibiting the activity of AREG receptor EGFR on the progression of pulmonary fibrosis. Cdc42AT2 gene-null mice treated with PNX were treated with PBS alone or with the EGFR inhibitor gefitinib from day 6 to day 30 after PNX ( Fig.13 A). It was found that gefitinib treatment also significantly inhibited the development of fibrosis in the lungs of mice with Cdc42 AT2 gene null ( Fig.13 B).
[0163] Together, these results suggest that blocking AREG and its receptor EGFR is an ideal therapeutic approach for the treatment of IPF and other fibrotic diseases.
[0164] References:
[0165] 1Wynn, T.A. Cellular and molecular mechanisms of fibrosis, The Journal of pathology 214, 199-210, doi: 10.1002 / path.2277 (2008).
[0166] 2Wynn, TA & Ramalingam, TR Mechanisms of fibrosis: therapeutic translation for fibrotic disease, Nature medicine 18, 1028-1040, doi: 10.1038 / nm.2807 (2012).
[0167] 3Mehal, WZ, Iredale, J. & Friedman, SL Scraping fibrosis: expressway to the core of fibrosis, Nature medicine 17, 552-553, doi: 10.1038 / nm0511-552 (2011).
[0168] 4Barkauskas, CE & Noble, PW Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis, American journal of physiology. Cell physiology 306, C987-996, doi: 10.1152 / ajpcell.00321.2013 (2014).
[0169] 5 Rock, JR et al., Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition, Proceedings of the National Academy of Sciences of the United States of America 108, E1475-1483, doi: 10.1073 / pnas.1117988108 (2011).
[0170] 6Gross, TJ & Hunninghake, GW Idiopathic pulmonary fibrosis, New England Journal of Medicine 345, 517-525 (2001).
[0171] 7Vyalov, SL, Gabbiani, G. & Kapanci, Y. Rat alveolar myofibroblasts acquire alpha-smooth muscle actin expression during bleomycin-induced pulmonary fibrosis, The American journal of pathology 143, 1754 (1993).
[0172] 8 King Jr, TE, Pardo, A. & Selman, M. Idiopathic pulmonary fibrosis, The Lancet 378, 1949-1961 (2011).
[0173] 9Plantier, L. et al., Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis, Thorax 66, 651-657, doi: 10.1136 / thx.2010.151555 (2011).
[0174] 10Steele, MP & Schwartz, DA Molecular mechanisms in progressive idiopathic pulmonary fibrosis, Annual review of medicine 64, 265-276, doi:10.1146 / annurev-med-042711-142004 (2013).
[0175] 11Camelo, A., Dunmore, R., Sleeman, MA & Clarke, DL. The epithelium in idiopathic pulmonary fibrosis: breaking the barrier, Frontiers in pharmacology 4, 173, doi: 10.3389 / fphar.2013.00173 (2014).
[0176] 12Barkauskas, CE et al., Type 2 alveolar cells are stem cells in adult lung, The Journal of clinical investigation 123, 3025-3036, doi: 10.1172 / JCI68782 (2013).
[0177] 13 Desai, TJ, Brownfield, DG & Krasnow, MA Alveolar progenitor and stem cells in lung development, renewal and cancer, Nature 507, 190-194, doi: 10.1038 / nature12930 (2014).
[0178] 14Haies, DM, Gil, J. & Weibel, ER Morphometric study of rat lung cells: I. Numerical and dimensional characteristics of parenchymal cell population, American Review of Respiratory Disease 123, 533-541 (1981).
[0179] 15Selman, M. & Pardo, A. Idiopathic pulmonary fibrosis: an epithelial / fibroblastic cross-talk disorder, Respiratory research 3, 3 (2001).
[0180] 16 Kropski, JA, Blackwell, TS & Loyd, JE The genetic basis of idiopathic pulmonary fibrosis, European Respiratory Journal 45, 1717-1727 (2015).
[0181] 17Goodwin, AT & Jenkins, G. Molecular endotyping of pulmonary fibrosis, Chest 149, 228-237 (2016).
[0182] 18Xu, Y. et al., Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis, JCI insight 1 (2016).
[0183] 19Sternlicht, MD & Sunnarborg, SW The ADAM17–amphiregulin–EGFR axis in mammary development and cancer, Journal of mammary gland biology and neoplasia 13, 181-194 (2008).
[0184] 20Berasain, C. & Avila, MA Seminars in cell & developmental biology, 31-41 (Elsevier).
[0185] 21 Sternlicht, MD, et al., Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin, Development 132, 3923-3933 (2005).
[0186] 22Macias, H. & Hinck, L. Mammary gland development, Wiley Interdisciplinary Reviews: Developmental Biology 1, 533-557 (2012).
[0187] 23(!!!Broken reference!!!).
[0188] 24Busser, B., Sancey, L., Brambilla, E., Coll, J.-L. & Hurbin, A. The multiple roles of amphiregulin in human cancer, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1816, 119-131 (2011).
[0189] 25 Chen, Z. et al., Aberrantly activated AREG–EGFR signaling is required for the growth and survival of CRTC1–MAML2 fusion-positive mucoepidermoid carcinoma cells, Oncogene 33, 3869 (2014).
[0190] 26Busser, B. et al., Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation, Molecular Therapy 18, 536-543 (2010).
[0191] 27 Wang, X., Masri, S., Phung, S. & Chen, S. The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop, Cancer research 68, 2259-2265 (2008).
[0192] 28 Zhou, Y. et al., Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis, Journal of Biological Chemistry 287, 41991-42000 (2012).
[0193] 29Steele, MP & Schwartz, DA Molecular mechanisms in progressive idiopathic pulmonary fibrosis, Annual review of medicine 64, 265-276 (2013).
[0194] 30 Chen, L. et al., Cdc42 deficiency causes Sonic hedgehog-independent holoprosencephaly, Proceedings of the National Academy of Sciences 103, 16520-16525 (2006).
[0195] 31Council, NR Guide for the care and use of laboratory animals (National Academies Press, 2010).
[0196] 32Foltz, CJ & Ullman-Cullere, M. Guidelines for assessing the health and condition of mice, Resource 28 (1999).
[0197] 33 Luetteke, NC, et al., Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development, Development 126, 2739-2750 (1999).
[0198] 34 Wang, Y. et al., Pulmonary alveolar type I cell population consists of two distinct subtypes that differin cell fate, Proceedings of the National Academy of Sciences, 201719474 (2018).
[0199] 35Lynch, DA et al., Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper, The Lancet Respiratory Medicine 6, 138-153, doi:10.1016 / s2213-2600(17)30433-2 (2018).
Claims
1. A drug target for idiopathic pulmonary fibrosis, which is AREG signaling in AT2 cells of the lung of an animal or human.
2. The drug target according to claim 1, wherein AREG is detected in AT2 cells of the lungs of animals and humans with idiopathic pulmonary fibrosis (IPF) but is not expressed in AT2 cells of normal lungs of animals or humans, such as / or AREG is detected in AT2 cells of the Cdc42AT2 gene null lung, and after PNX, the expression level of AREG is increased in AT2 cells of the Cdc42AT2 gene null lung; and / or The expression level of AREG is upregulated in AT2 cells of the lungs of animals or humans with progressive fibrosis.
3. The drug target according to claim 1 or 2, wherein the AREG signaling in the AT2 cells of the lung of an animal or a human comprises AREG and / or a receptor of AREG in the AT2 cells of the lung of an animal or a human, Preferably, the receptor of AREG is EGFR in animal or human lung fibroblasts, preferably EGFR in α-SMA positive fibroblasts. Preferably, the drug target reduces the expression level of AREG in AT2 cells of the lung of an animal or human.
4. A method for producing a transgenic mouse in which Areg is overexpressed in AT2 cells, wherein AREG is overexpressed specifically in AT2 cells in the lung of the mouse.
5. The method according to claim 4, wherein the transgenic mouse produced is a Spc-rtTA; teto-Areg mouse, such as / or The method comprises the step of specifically inducing Areg expression in AT2 cells after doxycycline treatment; and / or The Spc-rtTA;teto-Areg mouse has the characteristic sequence shown in SEQ ID NO: 18, and / or The Spc-rtTA;teto-Areg mice were identified using a primer pair having the following sequences: Forward: GTACCCGGGATGAGAACTCCG (SEQ ID NO: 19); Reverse: GCCGGATATTTGTGGTTCATT (SEQ ID NO: 20).
6. Use of a substance targeting a drug target as claimed in any one of claims 1 to 3 in the preparation of a drug for treating pulmonary fibrosis in animals and humans, in particular idiopathic pulmonary fibrosis (IPF).
7. The use according to claim 6, wherein the substance is an AREG inhibitor in pulmonary AT2 cells or an EGFR inhibitor in pulmonary fibroblasts, and the substance preferably reduces the expression level or activity of AREG in pulmonary AT2 cells of animals or humans, or reduces the expression level or activity of EGFR in pulmonary fibroblasts.
8. A method for screening a drug for treating pulmonary fibrosis in animals or humans, particularly idiopathic pulmonary fibrosis (IPF), the method comprising the step of screening a drug for treating pulmonary fibrosis in animals or humans, particularly idiopathic pulmonary fibrosis (IPF) using a transgenic mouse produced by the drug target described in any one of claims 1 to 3 or the method described in claim 4 or 5.
9. Use of a detection agent for a drug target as claimed in any one of claims 1 to 3 in the manufacture of a diagnostic kit for diagnosing pulmonary fibrosis in animals or humans, in particular idiopathic pulmonary fibrosis (IPF), Preferably, the kit is for use with samples from animals or humans suspected of having pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF); Preferably, the sample is a biopsy tissue, such as lung tissue from an animal or human, preferably from the lower, middle or upper part of a lung lobe of the animal or human; Preferably, increased expression of AREG is detected in AT2 cells from the lung of an animal or human, and the animal or human is diagnosed as suffering from severe pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
10. The drug target of any one of claims 1 to 3, the use of claim 6 or 7, the method of claim 8 or the use of claim 9, wherein the animal is a mouse, rabbit, rat, dog, pig, horse, cow, sheep, monkey or chimpanzee.
